Metabolic Profiling Analysis of Patients With Coronary Heart Disease Undergoing Xuefu Zhuyu Decoction Treatment
| Autor: | Tianqi Tao, Xiao-Reng Wang, Xiu-Hua Liu, Tao He |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Spermine Decoction Traditional Chinese medicine Carbohydrate metabolism Pharmacology Placebo 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Metabolomics Medicine Pharmacology (medical) ethnopharmacology coronary heart disease Xuefu Zhuyu decoction LC-MS/MS Original Research Fatty acid metabolism business.industry lcsh:RM1-950 metabolomics Metabolic pathway lcsh:Therapeutics. Pharmacology 030104 developmental biology chemistry 030220 oncology & carcinogenesis business |
| Zdroj: | Frontiers in Pharmacology, Vol 10 (2019) Frontiers in Pharmacology |
| ISSN: | 1663-9812 |
| DOI: | 10.3389/fphar.2019.00985 |
| Popis: | Coronary heart disease (CHD) remains the leading cause of morbidity and mortality worldwide. Traditional Chinese medicine (TCM) is one of the effective complementary and alternative therapies used to improve the prognosis of CHD patients. Xuefu Zhuyu (XFZY) decoction, a classical traditional Chinese medication for regulating Qi and promoting blood circulation, has a clinical benefit in CHD; however, the underlying mechanism is not clear. Recently, it was found that the metabolites involved in amino acid metabolism and the tricarboxylic acid cycle were altered in CHD patients with Qi and Yin deficiency syndrome. To understand the material foundation of Qi, it is of great significance to study the differential metabolites involved in Qi during treatment of CHD with Qi-regulating and blood-promoting herbs. In this study, we investigated the metabolic profiles of serum in CHD patients by nontargeted metabolomics analysis to detect differential metabolites between the XFZY decoction group and placebo group. Ten CHD patients were enrolled and treated with placebo granules or XFZY decoction granules in a random and double-blind manner. Serum samples of all patients were evaluated by untargeted high-performance liquid chromatography with tandem mass spectrometry-based metabolomics. In total, 513 metabolites were detected in the serum of CHD patients, and six of these metabolites participating in seven metabolic pathways were significantly different between CHD patients treated with XFZY decoction and the placebo group. Among the six differential metabolites, FA (20:2)-H and tetracarboxylic acid (24:0), involved in fatty acid metabolism; cis-aconitic acid, which participates in the tricarboxylic acid cycle; 2-deoxy-D-glucose, involved in glucose metabolism; and N-acetylglycine, involved in amino acid metabolism, were decreased, whereas spermine, which participates in amino acid metabolism, was increased as compared with the placebo group. Our findings, combined with the perspective of biological functions, indicate that 2-deoxy-D-glucose and spermine might constitute the partial material foundation of Qi in CHD patients treated with XFZY decoction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|